{"id":745554,"date":"2017-05-17T16:00:00","date_gmt":"2017-05-17T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/"},"modified":"2025-11-07T01:26:32","modified_gmt":"2025-11-07T06:26:32","slug":"data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/","title":{"rendered":"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       Research with KEYTRUDA in Monotherapy and in Combination Includes        Findings in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Urothelial        Carcinoma, Microsatellite-Instability High (MSI-H) Cancers, Gastric        Cancer and Breast Cancer     <\/p>\n<p class=\"bwalignc\">       New Overall Survival Data to be Presented in NSCLC, Melanoma and        Urothelial Carcinoma     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new and updated data from studies of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, will be presented at<br \/>\n      the 53<sup>rd<\/sup> Annual Meeting of the American Society of Clinical<br \/>\n      Oncology (ASCO) in Chicago, June 2 \u2013 6, 2017. At this year\u2019s meeting,<br \/>\n      researchers will present data from more than 50 abstracts investigating<br \/>\n      the use of KEYTRUDA as monotherapy and in novel combinations across 16<br \/>\n      cancers, including non-small cell lung cancer (NSCLC), melanoma,<br \/>\n      urothelial carcinoma, microsatellite instability-high (MSI-H) cancers,<br \/>\n      gastric cancer and breast cancer. Additional longer-term<br \/>\n      progression-free survival (PFS) and overall survival (OS) data for<br \/>\n      KEYTRUDA in monotherapy and as a combination therapy in first-line NSCLC<br \/>\n      from KEYNOTE-024 and KEYNOTE-021G will be presented. As noted in the<br \/>\n      abstracts, in KEYNOTE-024 significant improvement in OS was maintained<br \/>\n      with KEYTRUDA compared to chemotherapy with a longer follow-up of<br \/>\n      approximately six months; and in KEYNOTE-021G with more than five months<br \/>\n      of additional follow-up, a trend for improved OS with KEYTRUDA in<br \/>\n      combination with pemetrexed and carboplatin (pem\/carbo) was observed<br \/>\n      when compared to pem\/carbo alone, despite high rates of patient<br \/>\n      cross-over. Additional data on these findings will be presented at the<br \/>\n      meeting.\n    <\/p>\n<p>\n      \u201cOur data at ASCO bring to life the potential of KEYTRUDA across many<br \/>\n      different cancer types as both monotherapy and in combination, and<br \/>\n      underscore the remarkable progress that is being made in the fight<br \/>\n      against cancer,\u201d said Dr. Roy Baynes, senior vice president and head of<br \/>\n      global clinical development, Chief Medical Officer, Merck Research<br \/>\n      Laboratories. \u201cIn particular, we continue to show improved survival<br \/>\n      outcomes in the first-line treatment of both melanoma and non-small cell<br \/>\n      lung cancer, and we highlight clinical collaboration data that explore<br \/>\n      the potential of novel immunotherapy combinations as a treatment for<br \/>\n      patients with cancer.\u201d\n    <\/p>\n<p>\n      In monotherapy, data for KEYTRUDA (pembrolizumab) will be presented in<br \/>\n      NSCLC, melanoma, urothelial carcinoma, gastric cancer and<br \/>\n      triple-negative breast cancer (TNBC), among others. In the combination<br \/>\n      setting, data for KEYTRUDA in NSCLC, TNBC and endometrial cancer, among<br \/>\n      others, will be presented. Additionally, studies providing insight into<br \/>\n      the role of biomarkers \u2013 such as PD-L1 and microsatellite-instability \u2013<br \/>\n      across a variety of tumors and treatment settings will be presented.<br \/>\n      Merck continues to advance the study of genomic markers and signals that<br \/>\n      can help physicians to identify the treatment regimen that may be best<br \/>\n      for each patient.\n    <\/p>\n<p>\n      <b>Merck Data at the 2017 ASCO Annual Meeting<\/b>\n    <\/p>\n<p>\n      A select listing of the more than 50 Merck-sponsored and collaboration<br \/>\n      abstracts featuring KEYTRUDA is provided below. Data from studies of<br \/>\n      other oncology medicines in Merck\u2019s portfolio and pipeline will also be<br \/>\n      presented at the meeting. For more information, including a complete<br \/>\n      list of abstract titles and presentation days and times, please visit<br \/>\n      the ASCO website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fiplanner.asco.org%2Fam2017&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=https%3A%2F%2Fiplanner.asco.org%2Fam2017%2F%23%2F&amp;index=1&amp;md5=c5af61ab6684918dc876ca7755c4be88\" rel=\"nofollow\">https:\/\/iplanner.asco.org\/am2017\/#\/<\/a>.\n    <\/p>\n<p>\n      <b>Advanced Bladder Cancers: <\/b>Merck has the largest immuno-oncology<br \/>\n      development program in bladder cancer. In monotherapy, OS results from<br \/>\n      KEYNOTE-045, the phase 3 trial of KEYTRUDA compared to chemotherapy for<br \/>\n      patients with locally advanced or metastatic advanced urothelial<br \/>\n      carcinoma (a type of bladder cancer) in the second-line setting<br \/>\n      (Abstract #4501), will be presented. In addition, a biomarker analysis<br \/>\n      from KEYNOTE-052, the phase 2 trial of patients with advanced urothelial<br \/>\n      carcinoma in the first-line setting who are not eligible for<br \/>\n      cisplatin-based chemotherapy (Abstract #4502), will also be presented;<br \/>\n      data from both studies served as the basis for supplemental Biologics<br \/>\n      License Applications (sBLAs) for KEYTRUDA that are currently under<br \/>\n      review with the U.S. Food and Drug Administration (FDA). In the<br \/>\n      combination setting, new data will be presented from the phase 1\/2<br \/>\n      ECHO-202\/KEYNOTE-037 study of KEYTRUDA (pembrolizumab) and Incyte\u2019s<br \/>\n      investigational oral selective IDO1 enzyme inhibitor, epacadostat, in<br \/>\n      patients with advanced urothelial carcinoma (Abstract #4503).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4501 Oral Session: Planned survival analysis from<br \/>\n        KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro)<br \/>\n        versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced<br \/>\n        urothelial cancer (UC). D. Bajorin. Monday, June 5. 8:12 a.m. &#8211; 8:24<br \/>\n        a.m. CDT. Location: Arie Crown Theater.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4502 Oral Session: Biomarker findings and mature clinical<br \/>\n        results from KEYNOTE-052: First-line pembrolizumab (pembro) in<br \/>\n        cisplatin-ineligible advanced urothelial cancer (UC). P. O&#8217;Donnell.<br \/>\n        Monday, June 5. 8:24 a.m. &#8211; 8:36 a.m. CDT. Location: Arie Crown<br \/>\n        Theater.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4503 Oral Session: Epacadostat plus pembrolizumab in<br \/>\n        patients with advanced urothelial carcinoma: Preliminary phase I\/II<br \/>\n        results of ECHO-202\/KEYNOTE-037. D. Smith. Monday, June 5. 8:36 a.m. &#8211;<br \/>\n        8:48 a.m. CDT. Location: Arie Crown Theater.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Breast Cancer and Other Women\u2019s Cancers: <\/b>Merck is<br \/>\n      currently conducting several studies investigating the potential for<br \/>\n      KEYTRUDA as a monotherapy and as a combination therapy in breast cancer,<br \/>\n      and in endometrial, ovarian and cervical cancers. Monotherapy data to be<br \/>\n      presented include two of the phase 2 KEYNOTE-086 study cohorts (A &amp; B)<br \/>\n      of KEYTRUDA in patients with metastatic TNBC with varying levels of<br \/>\n      PD-L1 expression (Abstract #1008 and Abstract #1088, respectively). In<br \/>\n      the combination setting, findings will be presented investigating<br \/>\n      KEYTRUDA with chemotherapy in the neoadjuvant treatment setting for<br \/>\n      high-risk breast cancer (or TNBC) (Abstract #556 and Abstract #506,<br \/>\n      respectively), including results from the phase 2 I-SPY 2 TRIAL.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #1008 Oral Session: Phase 2 study of pembrolizumab<br \/>\n        (pembro) monotherapy for previously treated metastatic triple-negative<br \/>\n        breast cancer (mTNBC): KEYNOTE-086 cohort A. S. Adams. Saturday, June<br \/>\n        3. 3:39 p.m. &#8211; 3:51 p.m. CDT. Location: Hall D1.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #1088 Poster Session: Phase 2 study of pembrolizumab as<br \/>\n        first-line therapy for PD-L1\u2013positive metastatic triple-negative<br \/>\n        breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. S.<br \/>\n        Adams. Sunday, June 4. 8:00 a.m. &#8211; 11:30 a.m. CDT. Location: Hall A.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #506 Oral Session: Pembrolizumab plus standard neoadjuvant<br \/>\n        therapy for high-risk breast cancer (BC): Results from I-SPY 2. R.<br \/>\n        Nanda. Monday, June 5. 11:45 a.m. &#8211; 11:57 a.m. CDT. Location: Hall D2.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #556 Poster Session: Pembrolizumab (pembro) + chemotherapy<br \/>\n        (chemo) as neoadjuvant treatment for triple negative breast cancer<br \/>\n        (TNBC): Preliminary results from KEYNOTE-173. P. Schmid. Sunday, June<br \/>\n        4. 8:00 a.m. &#8211; 11:30 a.m. CDT. Location: Hall A.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Gastrointestinal&nbsp;(GI) Cancers: <\/b>Data will be<br \/>\n      presented from the phase 2 registrational KEYNOTE-059 study of KEYTRUDA<br \/>\n      (pembrolizumab) in patients with advanced gastric cancer \u2013 the<br \/>\n      monotherapy cohort (Abstract #4003) and the combination cohort (Abstract<br \/>\n      #4012). Additionally, combination data from the clinical collaboration<br \/>\n      with Eli Lilly and Company investigating KEYTRUDA with ramucirumab will<br \/>\n      be presented (Abstract #4046).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4003 Oral Session: KEYNOTE-059 cohort 1: Efficacy and<br \/>\n        safety of pembrolizumab (pembro) monotherapy in patients with<br \/>\n        previously treated advanced gastric cancer. C. Fuchs. Sunday, June 4.<br \/>\n        9:00 a.m. &#8211; 9:12 a.m. CDT. Location: Hall D2.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4012 Poster Session\/Discussion: KEYNOTE-059 cohort 2:<br \/>\n        Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil<br \/>\n        (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric<br \/>\n        cancer. YJ. Bang. Saturday, June 3. Poster: 8:00 a.m. &#8211; 11:30 a.m.<br \/>\n        CDT. Location: Hall A. Discussion: 4:45 p.m. &#8211; 6:00 p.m. CDT.<br \/>\n        Location: Hall D2.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4046 Poster Session: Ramucirumab (R) plus pembrolizumab<br \/>\n        (P) in treatment naive and previously treated advanced gastric or<br \/>\n        gastroesophageal junction (G\/GEJ) adenocarcinoma: A multi-disease<br \/>\n        phase I study. I. Chau. Saturday, June 3. 8:00 a.m. &#8211; 11:30 a.m. CDT.<br \/>\n        Location: Hall A.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Head and Neck Cancer: <\/b>In advanced head and neck squamous<br \/>\n      cell carcinoma (HNSCC), a study evaluating the role of genomic<br \/>\n      determinants of response to KEYTRUDA monotherapy (Abstract #6009) will<br \/>\n      be presented. In the combination setting, researchers will present data<br \/>\n      from the ECHO-202\/KEYNOTE-037 trial, which is studying KEYTRUDA in<br \/>\n      combination with Incyte\u2019s epacadostat (Abstract #6010).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #6009 Clinical Science Symposium: Genomic determinants of<br \/>\n        response to pembrolizumab in head and neck squamous cell carcinoma<br \/>\n        (HNSCC). R. Haddad. Tuesday, June 6. 8:00 a.m. &#8211; 8:12 a.m. CDT.<br \/>\n        Location: S100a.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #6010 Clinical Science Symposium: Epacadostat plus<br \/>\n        pembrolizumab in patients with SCCHN: Preliminary phase I\/II results<br \/>\n        from ECHO-202\/KEYNOTE-037. O. Hamid. Tuesday, June 6. 8:12 a.m. &#8211; 8:24<br \/>\n        a.m. CDT. Location: S100a.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Lung Cancer: <\/b>Merck is continuing to advance<br \/>\n      understanding of the important role of KEYTRUDA (pembrolizumab) in<br \/>\n      metastatic lung cancer both as monotherapy and in combination with other<br \/>\n      therapies. In monotherapy, PFS and updated OS data from the phase 3<br \/>\n      KEYNOTE-024 trial of patients with advanced NSCLC whose tumors have high<br \/>\n      PD-L1 expression [tumor proportion score (TPS) \u226550%] (Abstract #9000)<br \/>\n      will be presented. In the combination setting, additional follow-up will<br \/>\n      be presented from the phase 1\/2 KEYNOTE-021G study (Abstract #9094),<br \/>\n      including OS. KEYNOTE-021G was the basis of the recent approval of<br \/>\n      KEYTRUDA in combination with pemetrexed and carboplatin for the<br \/>\n      first-line treatment of metastatic nonsquamous NSCLC, irrespective of<br \/>\n      PD-L1 expression. In addition, data will be presented from<br \/>\n      ECHO-202\/KEYNOTE-037 investigating KEYTRUDA with epacadostat in patients<br \/>\n      with NSCLC (Abstract #9014).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #9000 Oral Session: Progression after the next line of<br \/>\n        therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC<br \/>\n        and PD-L1 tumor proportion score (TPS) \u226550% enrolled in KEYNOTE-024.<br \/>\n        J. Brahmer. Tuesday, June 6. 9:45 a.m. &#8211; 9:57 a.m. CDT. Location: Hall<br \/>\n        D1.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #9094 Poster Session: First-line carboplatin and<br \/>\n        pemetrexed (CP) with or without pembrolizumab (pembro) for advanced<br \/>\n        nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. V.<br \/>\n        Papadimitrakopoulou. Saturday, June 3. 8:00 a.m. &#8211; 11:30 a.m. CDT.<br \/>\n        Location: Hall A.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #9014 Poster Session\/Discussion: Efficacy and safety of<br \/>\n        epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase<br \/>\n        I\/II results of ECHO-202\/KEYNOTE-037. T. Gangadhar. Saturday, June 3.<br \/>\n        Poster: 8:00 a.m. &#8211; 11:30 a.m. CDT. Location: Hall A. Discussion: 3:00<br \/>\n        p.m. &#8211; 4:15 p.m. CDT. Location: Hall D2.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Melanoma: <\/b>In monotherapy, longer-term OS data from the<br \/>\n      phase 3 KEYNOTE-006 trial (Abstract #9504) of KEYTRUDA will be<br \/>\n      presented. In combination studies, early findings from the phase 1b\/2<br \/>\n      KEYNOTE-184 study of Dynavax\u2019s intratumoral SD-101 in combination with<br \/>\n      KEYTRUDA in anti-PD-1 na\u00efve and experienced metastatic melanoma patients<br \/>\n      (Abstract #9550) will be presented, as will updated data from the<br \/>\n      KEYNOTE-029 study of KEYTRUDA with ipilimumab (Abstract #9545). In<br \/>\n      addition, data from the phase 2 KEYNOTE-142 study of Syndax\u2019s entinostat<br \/>\n      in combination with KEYTRUDA (pembrolizumab) in patients with advanced<br \/>\n      melanoma (Abstract #9529) will be presented for the first time.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #9504 Oral Session: Long-term outcomes in patients (pts)<br \/>\n        with ipilimumab (ipi)-naive advanced melanoma in the phase 3<br \/>\n        KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. C.<br \/>\n        Robert. Sunday, June 4. 9:12 a.m. &#8211; 9:24 a.m. CDT. Location: Arie<br \/>\n        Crown Theater.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract&nbsp;#9550 Poster Session: Phase 1b\/2, open label, multicenter,<br \/>\n        study of intratumoral SD-101 in combination with&nbsp;pembrolizumab&nbsp;in<br \/>\n        anti-PD1 na\u00efve &amp; experienced metastatic melanoma patients. A. Leung.<br \/>\n        Saturday, June 3. 1:15 p.m. &#8211; 4:45 p.m. CDT. Location: Hall A.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #9545 Poster Session: KEYNOTE-029: Efficacy and safety of<br \/>\n        pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. M.<br \/>\n        Carlino. Saturday, June 3. 1:15 p.m. &#8211; 4:45 p.m. CDT. Location: Hall A.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #9529 Poster Session: Melanoma\/Skin Cancers, ENCORE 601: A<br \/>\n        phase II study of entinostat (ENT) in combination with pembrolizumab<br \/>\n        (PEMBRO) in patients with melanoma. M. Johnson. Saturday, June 3. 1:15<br \/>\n        p.m. &#8211; 4:45 p.m. CDT. Location: Hall A.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Microsatellite-Instability (MSI) High Cancers: <\/b>Merck is<br \/>\n      advancing the use of biomarkers to guide clinical decision making,<br \/>\n      including for patients with MSI-High advanced malignancies. At ASCO,<br \/>\n      monotherapy data from KEYNOTE-164 and KEYNOTE-158 will be presented in<br \/>\n      patients with high levels of MSI (Abstract #3071).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #3071 Poster Session: Pembrolizumab therapy for<br \/>\n        microsatellite instability high (MSI-H) colorectal cancer (CRC) and<br \/>\n        non-CRC. L. Diaz. Monday, June 5. 8:00 a.m. &#8211; 11:30 a.m. CDT.<br \/>\n        Location: Hall A.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Renal Cell Carcinoma (RCC):<\/b> New data from studies of<br \/>\n      KEYTRUDA in combination in patients with advanced RCC will also be<br \/>\n      presented, including preliminary data for KEYTRUDA combined with<br \/>\n      epacadostat from the ECHO-202\/KEYNOTE-037 trial (Abstract #4515) and for<br \/>\n      KEYTRUDA combined with Novartis\u2019 pazopanib (Abstract #4506).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4515 Poster Session\/Discussion: Epacadostat plus<br \/>\n        pembrolizumab in patients with advanced RCC: Preliminary phase I\/II<br \/>\n        results from ECHO-202\/KEYNOTE-037. P. Lara. Sunday, June 4. Poster:<br \/>\n        8:00 a.m. &#8211; 11:30 a.m. CDT. Location: Hall A. Discussion: 11:30 a.m. &#8211;<br \/>\n        12:45 a.m. CDT. Location: Arie Crown Theater.<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract #4506 Oral Session: A phase I\/II study to assess the<br \/>\n        safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in<br \/>\n        patients (pts) with advanced renal cell carcinoma (aRCC). S.<br \/>\n        Chowdhury. Monday, June 5. 9:36 a.m. &#8211; 9:48 a.m. CDT. Location: Arie<br \/>\n        Crown Theater.<\/i>\n      <\/li>\n<\/ul>\n<p>\n      <b>Merck Investor Event<\/b>: Merck will hold an investor event in<br \/>\n      conjunction with the 2017 ASCO Annual Meeting on Monday, June 5 at 5:45<br \/>\n      p.m. CDT (6:45 p.m. EDT). Investors, analysts, members of the media and<br \/>\n      the general public are invited to listen to a live audio webcast of the<br \/>\n      presentation at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.merck.com%2Fevents-and-presentations%2Fdefault.aspx&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.merck.com%2Fevents-and-presentations%2Fdefault.aspx&amp;index=2&amp;md5=be377871349cfced9677f43786d55e1c\" rel=\"nofollow\">http:\/\/investors.merck.com\/events-and-presentations\/default.aspx<\/a><br \/>\n      or by dialing (866) 486-2604 \u2013 and using ID code number 3314336.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b> <b>Indications<br \/>\n      and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab), as a single agent, is also indicated for the<br \/>\n      treatment of patients with metastatic NSCLC whose tumors express PD-L1<br \/>\n      (TPS \u22651%) as determined by an FDA-approved test, with disease<br \/>\n      progression on or after platinum-containing chemotherapy. Patients with<br \/>\n      EGFR or ALK genomic tumor aberrations should have disease progression on<br \/>\n      FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA (pembrolizumab) for Grade 3 or 4<br \/>\n      hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider benefit of treatment with<br \/>\n      KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause severe or life-threatening<br \/>\n      infusion-related reactions, which have been reported in 6 (0.2%) of 2799<br \/>\n      patients. Monitor patients for signs and symptoms of infusion-related<br \/>\n      reactions, including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23&nbsp;patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6&nbsp;patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2&nbsp;patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade&nbsp;3&nbsp;to&nbsp;4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with pemetrexed and<br \/>\n      carboplatin, KEYTRUDA was discontinued in 10% of 59 patients. The most<br \/>\n      common adverse reaction resulting in discontinuation of KEYTRUDA (\u22652%)<br \/>\n      was acute kidney injury (3.4%). Adverse reactions leading to<br \/>\n      interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%).The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA (pembrolizumab) compared to carbo\/pem alone were<br \/>\n      fatigue (71% vs 50%), nausea (68% vs 56%), constipation (51% vs 37%),<br \/>\n      rash (42% vs 21%), vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea<br \/>\n      (37% vs 23%), decreased appetite (31% vs. 23%), headache (31% vs 16%),<br \/>\n      cough (24% vs 18%), dizziness (24%vs 16%), insomnia (24% vs 15%),<br \/>\n      pruritus (24% vs 4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs<br \/>\n      11%), alopecia (20% vs 3.2%), upper respiratory tract infection (20% vs<br \/>\n      3.2%), and arthralgia (15% vs 24%). The study was not designed to<br \/>\n      demonstrate a statistically significant difference in adverse reaction<br \/>\n      rates for KEYTRUDA plus chemotherapy, as compared to chemotherapy alone,<br \/>\n      for any specified adverse reaction.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=3&amp;md5=ed51ff7dca08790d624ac6dec300241c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=ea7b5184330b91c58e8bb48f4e4338d2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=34d968c98b20f679f13a738843177f0a\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=f50f634bea4ee113be5848173e512458\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=2855a7486e5abe9a3e1b8ef34df5ab68\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=017b71bef2b21e161b89290ebcf4c486\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=c174a65e922d03e35d31241acf869d42\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=6f923d79ad2d8060581b4346205953c1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=11&amp;md5=7516db0311dc920c871ee88d8d3faeb4\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51561203&amp;newsitemid=20170517006337&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=12&amp;md5=30a20b1c38d0c976a2814c11be959780\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170517006337r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney        Ronaldo, 908-740-6132<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, will be presented at the 53 rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2 \u2013 6, 2017. At this year\u2019s meeting, researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric cancer and breast cancer. Additional longer-term progression-free survival (PFS) and overall survival (OS) data for KEYTRUDA in monotherapy and as a combination therapy in first-line NSCLC from KEYNOTE-024 and KEYNOTE-021G will be presented. As noted in the abstracts, in KEYNOTE-024 significant improvement in OS was maintained with KEYTRUDA compared to chemotherapy with<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,137,138,289],"class_list":["post-745554","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, will be presented at the 53 rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2 \u2013 6, 2017. At this year\u2019s meeting, researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric cancer and breast cancer. Additional longer-term progression-free survival (PFS) and overall survival (OS) data for KEYTRUDA in monotherapy and as a combination therapy in first-line NSCLC from KEYNOTE-024 and KEYNOTE-021G will be presented. As noted in the abstracts, in KEYNOTE-024 significant improvement in OS was maintained with KEYTRUDA compared to chemotherapy with\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"22 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\\\/\",\"name\":\"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-05-17T16:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, will be presented at the 53 rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2 \u2013 6, 2017. At this year\u2019s meeting, researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric cancer and breast cancer. Additional longer-term progression-free survival (PFS) and overall survival (OS) data for KEYTRUDA in monotherapy and as a combination therapy in first-line NSCLC from KEYNOTE-024 and KEYNOTE-021G will be presented. As noted in the abstracts, in KEYNOTE-024 significant improvement in OS was maintained with KEYTRUDA compared to chemotherapy with","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:32+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"22 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/","name":"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-05-17T16:00:00+00:00","dateModified":"2025-11-07T06:26:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-across-16-types-of-cancer-from-mercks-industry-leading-immuno-oncology-program-to-be-presented-at-the-2017-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Data for KEYTRUDA\u00ae (pembrolizumab) Across 16 Types of Cancer from Merck\u2019s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f310bf07-1cc6-4325-bfce-c786be0c3928","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Data-for-KEYTRUDA-pembrolizumab-Across-16-Types-of-Cancer-from-Mercks-Industry-Leading-Immuno-Oncology-Program-to-Be-Presented-at-the-VJS99.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745554\/revisions"}],"predecessor-version":[{"id":3674918,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745554\/revisions\/3674918"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745554"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}